×
Please support independent journalism!
Already a subscriber? Please log in below. New to us? Please choose one of our offers and Get Started to become a subscriber.
Please support independent journalism!
Your current subscription does not provide access to this content.
All Access on your computer, phone & tablet
Replica Edition (PDF version)
Replica Edition (PDF version)
All Access on your computer, phone & tablet
Replica Edition (PDF version)
Seattle Children’s hospital is bringing in a big name to review its policies and practices surrounding institutional racism, equity and inclusion: former U.S. Attorney General Eric Holder.
News Category Global Banking & Finance Reviews
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy
Safety Profile Continues to be Favorable
EDINBURGH, United Kingdom, Jan. 15, 2021 NuCana plc (NASDAQ: NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.
NuTide:302 is a three-part study investigating NUC-3373, NuCana’s targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373’s optimal dose and schedule in combination with agents commonly used to treat patients with co